Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) has announced that topline data from its Phase 1/2 ABILITY-1 clinical trial of MDNA11 will be presented orally at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting on November 7, 2026, in Phoenix, Arizona. The abstract was selected as one of the Top 150 Abstracts at the conference, a distinction that may draw heightened attention from oncology investors and clinicians. The ABILITY-1 study evaluates MDNA11 in patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers.

Key Points

  • Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) is a Toronto and Houston-based clinical-stage immunotherapy company.
  • Topline data from the Phase 1/2 ABILITY-1 study of MDNA11 will be delivered as an oral presentation at SITC 2026 on November 7, 2026.
  • The abstract (Number 517) was selected among the Top 150 Abstracts at SITC 2026; the presentation runs from 4:30–4:45 p.m. MST at the Phoenix Convention Center, Room 301D.
  • Investors will be watching for clinical activity data in biomarker-enriched gastrointestinal malignancies, including ICI-refractory disease, presented in the oral session.

MDNA11 Oral Presentation Details at SITC 2026 in Phoenix

Medicenna's abstract, numbered 517, is titled "MDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory Disease." The presentation is scheduled for Saturday, November 7, 2026, from 4:30 to 4:45 p.m. MST as part of Oral Session 3 at the Phoenix Convention Center, Room 301D. The selection as one of the Top 150 Abstracts at a major oncology immunotherapy conference is considered a competitive distinction within the clinical research community.

ABILITY-1 Trial Scope and Patient Populations Being Evaluated

The Phase 1/2 ABILITY-1 study is evaluating MDNA11 in expansion cohorts comprising patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers. MDNA11 is described by the company as a long-acting IL-2 Superkine designed to selectively activate cancer-fighting immune cells. The oral presentation will cover data from both monotherapy and combination use with pembrolizumab, with particular focus on patients with ICI-refractory disease — a population with limited existing treatment options that investors in the oncology sector may find clinically significant.

Medicenna's Broader Immunotherapy Pipeline Context

Beyond MDNA11, Medicenna is also advancing bizaxofusp, a targeted IL-4 Empowered Superkine evaluated in more than 130 patients, which has received Fast Track and Orphan Drug designations from the FDA in recurrent glioblastoma. Additional pipeline assets include MDNA113, a PD-1 x IL-2 bifunctional immunotherapy, and MDNA209, an antagonist of CD122 blocking IL-2/IL-15 signalling. The immediate share price impact was not clear from available public information.